Neuromodulation and Non-Pharmacological Treatment of Migraine
Journal Title: Neuro – Open Journal - Year 2016, Vol 3, Issue 1
Abstract
Migraine is a chronic brain disorder that is believed to be due to dysfunction of the brain and brainstem that result in dysmodulation of sensory processing of the head and vascular tone. The exact pathomechanism of migraine is not known but some genes including mutations in the sodium and calcium channels and Na+/K+ pump have been implicated in migraine with aura.1-8 Several drugs are currently used in the acute and preventive treatment of migraine. These include the non-steroidal anti-inflammatory drugs, the triptan family, anti-epileptic drugs, beta-blockers, calcium channel blockers, steroids, and recently antibodies against calcitonin gene-related peptide (CGRP) or its receptor among other drugs.5,9 Some other drugs are under investigation and the CGRP receptor antagonists (the gepant family drugs), were discontinued although other drugs in this category are still under investigation.10-16 However, there are some medically intractable headaches or unsatisfactory patient management or medications are poorly tolerated, therefore, additional treatment options might be helpful.
Authors and Affiliations
Mohtashem Samsam
Keywords
Related Articles
- EP ID EP552547
- DOI 10.17140/NOJ-3-e006
- Views 120
- Downloads 0
The Diagnostic Role of Neuromuscular Ultrasound in Chronic Inflammatory Demyelinating Polyneuropathy
The immune-neuropathies are a heterogenous group of peripheral nerve disorders. Their diagnostic classification is mainly based on the documentation of the distribution pattern of peripheral nerve impairment and the resu...
CNS Complication of Group A Streptococcal Meningitis in Children: a Comprehensive Case-Based Literature Review
Group A Streptococcus pyogenes meningitis rarely results in central nervous system complication. Chronic hydrocephalus is a well-known complication of bacterial meningitis. To date, no reports have focused on acute centr...
Mobile Stroke Unit (MSU): The Future of Acute Stroke Treatment?
Time is the key factor in brain survivability in acute stroke treatment.1The therapeutic effects of intravenous recombinant tissue Plasminogen Activator (IV rtPA) are highly dependent on time.1-3 Stroke patients presenti...
Acute Polyneuropathy in Children with Acute Lymphocytic Leukemia: Case Report and Systemic Review of the Literature
Acute polyneuropathy in children with acute lymphoblastic leukemia is extremely rare, but its onset and association with Guillain-Barré syndrome presents a diagnostic challenge. We report a 5-year-old boy who presented w...
Clinical Data Associated With the Therapeutic Response to Glatiramer Acetate in Multiple Sclerosis Patients
Background: The increasing appearance of new drugs is making more difficult the choice of treatment in multiple sclerosis. According to different criteria, between 20 to 50% of the patients with multiple sclerosis (MS) t...